Latest Toca 511 & Toca FC Stories
Following Meeting with FDA, Company Advances Towards Pivotal Phase 2/3 Trial in Patients with Recurrent High Grade Glioma WASHINGTON, May 4, 2015 /PRNewswire/ --
SAN DIEGO, April 30, 2015 /PRNewswire/ -- Tocagen Inc., a clinical-stage immuno-oncology company, today announced updated
Results Presented at the 19th Annual Scientific Meeting and Education Day of the Society for Neuro-Oncology MIAMI, Nov.
In Addition, Toca 511 Clinical Data to be Presented at American Society of Clinical Oncology Annual Meeting SAN DIEGO, May 22, 2014 /PRNewswire/ --
Results Continue to Show Safety and Promising Survival; Program to Advance into a Randomized, Controlled Trial SAN DIEGO, April 10, 2014 /PRNewswire/ --
Intravenous Delivery Is An Important Advancement in the Development of Toca 511, Creates Opportunity For Use In Additional Cancer Indications SAN DIEGO, March 11, 2014 /PRNewswire/
- A handkerchief.
- In general, any miraculous portrait of Christ.